Halozyme Therapeutics Stock Performance
| HALO Stock | USD 63.75 1.41 2.16% |
On a scale of 0 to 100, Halozyme Therapeutics holds a performance score of 27. The company retains a Market Volatility (i.e., Beta) of 0.5, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Halozyme Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Halozyme Therapeutics is expected to be smaller as well. Please check Halozyme Therapeutics' semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Halozyme Therapeutics' current trending patterns will revert.
Risk-Adjusted Performance
Strong
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Halozyme Therapeutics are ranked lower than 27 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating essential indicators, Halozyme Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.31 | Five Day Return 4.11 | Year To Date Return 35.72 | Ten Year Return 369.11 | All Time Return 1.4 K |
Last Split Factor 171:40 | Last Split Date 2003-12-10 |
1 | Disposition of 7611 shares by Snyder Mark Howard of Halozyme Therapeutics subject to Rule 16b-3 | 01/03/2025 |
2 | Acquisition by Torley Helen of 10000 shares of Halozyme Therapeutics at 13.87 subject to Rule 16b-3 | 01/17/2025 |
3 | CHMP Issues Positive Opinion for Subcutaneous RYBREVANT Co-Formulated with ENHANZE for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung ... | 02/03/2025 |
4 | Disposition of 13092 shares by Torley Helen of Halozyme Therapeutics subject to Rule 16b-3 | 02/14/2025 |
5 | Heres Why Halozyme Therapeutics is a Strong Momentum Stock | 02/20/2025 |
6 | Disposition of 22436 shares by Torley Helen of Halozyme Therapeutics subject to Rule 16b-3 | 02/21/2025 |
7 | Disposition of 700 shares by Michael LaBarre of Halozyme Therapeutics at 58.67 subject to Rule 16b-3 | 02/25/2025 |
8 | Halozyme Therapeutics Inc to Present at TD Cowen 45th Annual Healthcare Conference | 02/26/2025 |
9 | Disposition of 100 shares by Michael LaBarre of Halozyme Therapeutics at 58.74 subject to Rule 16b-3 | 02/27/2025 |
10 | Halozyme Therapeutics Releases FY 2025 Earnings Guidance | 02/28/2025 |
11 | Morning Brew Nvidia-Backed CoreWeave to Acquire AI Platform Weights Biases | 03/03/2025 |
12 | Heres Why Halozyme Therapeutics is a Strong Value Stock | 03/05/2025 |
13 | Aperia Announces Exclusive Automatic Tire Inflation Agreement with Goodyear for Tires-as-a-Service Solution with Halo Connect i3 | 03/11/2025 |
14 | Disposition of 71810 shares by Torley Helen of Halozyme Therapeutics subject to Rule 16b-3 | 03/12/2025 |
15 | Is Brookdale Senior Living Stock Outpacing Its Medical Peers This Year | 03/13/2025 |
16 | Disposition of 17409 shares by Nicole LaBrosse of Halozyme Therapeutics subject to Rule 16b-3 | 03/14/2025 |
17 | Halozyme Therapeutics Inc Q4 2024 Earnings Call Highlights Record Revenue and Strong ... | 03/19/2025 |
18 | Halozyme Therapeutics is a Top-Ranked Value Stock Should You Buy | 03/21/2025 |
| Begin Period Cash Flow | 118.4 M |
Halozyme |
Halozyme Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,754 in Halozyme Therapeutics on December 24, 2024 and sell it today you would earn a total of 1,654 from holding Halozyme Therapeutics or generate 34.79% return on investment over 90 days. Halozyme Therapeutics is currently generating 0.5004% in daily expected returns and assumes 1.421% risk (volatility on return distribution) over the 90 days horizon. In different words, 12% of stocks are less volatile than Halozyme, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Halozyme Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Halozyme Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Halozyme Therapeutics, and traders can use it to determine the average amount a Halozyme Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.3521
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HALO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.42 actual daily | 12 88% of assets are more volatile |
Expected Return
| 0.5 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.35 actual daily | 27 73% of assets perform better |
Based on monthly moving average Halozyme Therapeutics is performing at about 27% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Halozyme Therapeutics by adding it to a well-diversified portfolio.
Halozyme Therapeutics Fundamentals Growth
Halozyme Stock prices reflect investors' perceptions of the future prospects and financial health of Halozyme Therapeutics, and Halozyme Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Halozyme Stock performance.
| Return On Equity | 1.98 | ||||
| Return On Asset | 0.18 | ||||
| Profit Margin | 0.44 % | ||||
| Operating Margin | 0.59 % | ||||
| Current Valuation | 8.96 B | ||||
| Shares Outstanding | 123.53 M | ||||
| Price To Earning | 60.08 X | ||||
| Price To Book | 22.13 X | ||||
| Price To Sales | 7.93 X | ||||
| Revenue | 1.02 B | ||||
| Gross Profit | 776.86 M | ||||
| EBITDA | 656.54 M | ||||
| Net Income | 444.09 M | ||||
| Cash And Equivalents | 209.36 M | ||||
| Cash Per Share | 1.52 X | ||||
| Total Debt | 1.51 B | ||||
| Debt To Equity | 4.28 % | ||||
| Current Ratio | 2.72 X | ||||
| Book Value Per Share | 2.96 X | ||||
| Cash Flow From Operations | 479.06 M | ||||
| Earnings Per Share | 3.43 X | ||||
| Market Capitalization | 8.05 B | ||||
| Total Asset | 2.06 B | ||||
| Retained Earnings | 359.87 M | ||||
| Working Capital | 946.24 M | ||||
| Current Asset | 171.77 M | ||||
| Current Liabilities | 62.46 M | ||||
About Halozyme Therapeutics Performance
By examining Halozyme Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Halozyme Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Halozyme Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 324.80 | 574.15 | |
| Return On Tangible Assets | 0.36 | 0.37 | |
| Return On Capital Employed | 0.29 | 0.30 | |
| Return On Assets | 0.22 | 0.23 | |
| Return On Equity | 1.22 | 1.28 |
Things to note about Halozyme Therapeutics performance evaluation
Checking the ongoing alerts about Halozyme Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Halozyme Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Halozyme Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Halozyme Therapeutics is a Top-Ranked Value Stock Should You Buy |
- Analyzing Halozyme Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Halozyme Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Halozyme Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Halozyme Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Halozyme Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Halozyme Therapeutics' stock. These opinions can provide insight into Halozyme Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.623 | Earnings Share 3.43 | Revenue Per Share | Quarterly Revenue Growth 0.295 | Return On Assets |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.